These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26048804)

  • 1. Use of molecular modeling aided design to dial out hERG liability in adenosine A(2A) receptor antagonists.
    Deng Q; Lim YH; Anand R; Yu Y; Kim JH; Zhou W; Zheng J; Tempest P; Levorse D; Zhang X; Greene S; Mullins D; Culberson C; Sherborne B; Parker EM; Stamford A; Ali A
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2958-62. PubMed ID: 26048804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of aminoquinazoline derivatives as human A(2A) adenosine receptor antagonists.
    Zhou G; Aslanian R; Gallo G; Khan T; Kuang R; Purakkattle B; De Ruiz M; Stamford A; Ting P; Wu H; Wang H; Xiao D; Yu T; Zhang Y; Mullins D; Hodgson R
    Bioorg Med Chem Lett; 2016 Feb; 26(4):1348-54. PubMed ID: 26781932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revisiting a receptor-based pharmacophore hypothesis for human A(2A) adenosine receptor antagonists.
    Bacilieri M; Ciancetta A; Paoletta S; Federico S; Cosconati S; Cacciari B; Taliani S; Da Settimo F; Novellino E; Klotz KN; Spalluto G; Moro S
    J Chem Inf Model; 2013 Jul; 53(7):1620-37. PubMed ID: 23705857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of the first sulfur-35-labeled hERG radioligand.
    Raab CE; Butcher JW; Connolly TM; Karczewski J; Yu NX; Staskiewicz SJ; Liverton N; Dean DC; Melillo DG
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1692-5. PubMed ID: 16377185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel adenosine A(2A) receptor ligands: a synthetic, functional and computational investigation of selected literature adenosine A(2A) receptor antagonists for extending into extracellular space.
    Jörg M; Shonberg J; Mak FS; Miller ND; Yuriev E; Scammells PJ; Capuano B
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3427-33. PubMed ID: 23602401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A
    Falsini M; Squarcialupi L; Catarzi D; Varano F; Betti M; Dal Ben D; Marucci G; Buccioni M; Volpini R; De Vita T; Cavalli A; Colotta V
    J Med Chem; 2017 Jul; 60(13):5772-5790. PubMed ID: 28590753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward a consensus model of the HERG potassium channel.
    Stary A; Wacker SJ; Boukharta L; Zachariae U; Karimi-Nejad Y; Aqvist J; Vriend G; de Groot BL
    ChemMedChem; 2010 Mar; 5(3):455-67. PubMed ID: 20104563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.
    Karczewski J; Wang J; Kane SA; Kiss L; Koblan KS; Culberson JC; Spencer RH
    Biochem Pharmacol; 2009 May; 77(10):1602-11. PubMed ID: 19426697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability.
    Moorjani M; Zhang X; Chen Y; Lin E; Rueter JK; Gross RS; Lanier MC; Tellew JE; Williams JP; Lechner SM; Malany S; Santos M; Ekhlassi P; Castro-Palomino JC; Crespo MI; Prat M; Gual S; Díaz JL; Saunders J; Slee DH
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1269-73. PubMed ID: 18249540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A
    Falsini M; Ceni C; Catarzi D; Varano F; Dal Ben D; Marucci G; Buccioni M; Martí Navia A; Volpini R; Colotta V
    Bioorg Med Chem Lett; 2020 Jun; 30(11):127126. PubMed ID: 32241719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High ligand efficiency quinazoline compounds as novel A
    Bolteau R; Duroux R; Laversin A; Vreulz B; Shiriaeva A; Stauch B; Han GW; Cherezov V; Renault N; Barczyk A; Ravez S; Coevoet M; Melnyk P; Liberelle M; Yous S
    Eur J Med Chem; 2022 Nov; 241():114620. PubMed ID: 35933788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular docking and molecular dynamics studies on the structure-activity relationship of fluoroquinolone for the HERG channel.
    Luo F; Gu J; Chen L; Xu X
    Mol Biosyst; 2014 Nov; 10(11):2863-9. PubMed ID: 25100024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding kinetics of ZM241385 derivatives at the human adenosine A2A receptor.
    Guo D; Xia L; van Veldhoven JP; Hazeu M; Mocking T; Brussee J; Ijzerman AP; Heitman LH
    ChemMedChem; 2014 Apr; 9(4):752-61. PubMed ID: 24591302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinazolin-4-piperidin-4-methyl sulfamide PC-1 inhibitors: alleviating hERG interactions through structure based design.
    Patel SD; Habeski WM; Cheng AC; de la Cruz E; Loh C; Kablaoui NM
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3339-43. PubMed ID: 19435660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Aminopyrimidines as dual adenosine A1/A2A antagonists.
    Robinson SJ; Petzer JP; Terre'Blanche G; Petzer A; van der Walt MM; Bergh JJ; Lourens AC
    Eur J Med Chem; 2015 Nov; 104():177-88. PubMed ID: 26462195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as potent GR antagonists with reduced hERG inhibition and an improved pharmacokinetic profile.
    Hunt HJ; Belanoff JK; Golding E; Gourdet B; Phillips T; Swift D; Thomas J; Unitt JF; Walters I
    Bioorg Med Chem Lett; 2015 Dec; 25(24):5720-5. PubMed ID: 26546213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selecting an optimal number of binding site waters to improve virtual screening enrichments against the adenosine A2A receptor.
    Lenselink EB; Beuming T; Sherman W; van Vlijmen HW; IJzerman AP
    J Chem Inf Model; 2014 Jun; 54(6):1737-46. PubMed ID: 24835542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs as adenosine A2A antagonists: the successful reduction of hERG activity. Part 2.
    Matasi JJ; Caldwell JP; Zhang H; Fawzi A; Higgins GA; Cohen-Williams ME; Varty GB; Tulshian DB
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3675-8. PubMed ID: 15982882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An automated docking protocol for hERG channel blockers.
    Di Martino GP; Masetti M; Ceccarini L; Cavalli A; Recanatini M
    J Chem Inf Model; 2013 Jan; 53(1):159-75. PubMed ID: 23259741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-go-Related Gene (hERG) Liabilities.
    Sakauchi N; Kohara Y; Sato A; Suzaki T; Imai Y; Okabe Y; Imai S; Saikawa R; Nagabukuro H; Kuno H; Fujita H; Kamo I; Yoshida M
    J Med Chem; 2016 Apr; 59(7):2989-3002. PubMed ID: 26954848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.